At AMWC, Allergan Aesthetics plans to launch its HArmonyCa hybrid injectable in several global markets.

Allergan Aesthetics will join industry colleagues and healthcare providers from around the globe for the 20th Anti-Aging Medicine World Congress in Monaco where it will launch the HArmonyCa hybrid injectiable in global markets.

The meeting marks Allergan Aesthetics’ entry into the emerging category of hybrid injectables with the launch of HArmonyCa with lidocaine across Europe. HArmonyCa will be launched in the UK, France, Germany, Spain, Italy, Sweden, Greece, Switzerland, Austria, the Netherlands.

It will also be available in select countries such as South Africa, Bulgaria, the Czech Republic, Slovakia, Romania, and Brazil.

The hybrid meeting will be held at Grimaldi Forum, Monaco, from March 31 to April 2.

The HArmonyCa Symposium will be held at Salle des Princes on March 31.

Allergan Aesthetics looks to further develop the hybrid injectables category by introducing its first dual-effect product, which combines the two active ingredients – hyaluronic acid (HA) – a well-known ingredient found in facial fillers and calcium hydroxyapatite (CaHA) – in one injection.

Allergan Aesthetics will provide a range of in-person and virtual training packages to support appropriate medical professionals who wish to offer HArmonyCa with lidocaine to their patients.

Hosted by Allergan Medical Institute (AMI), the main stage symposium titled ‘Face the Future’ will focus on the aesthetic trends of the future with sessions exploring the changing face of beauty, diversity, gender-inclusive beauty, and modern masculinity.

Photo 3026882 © Phillip Gray |